BioReliance

James J. Kramer, Ph.D., has been named vice president of operations, U.S. Biologics, BioReliance Corp. In his new position, Dr. Kramer is the U.S. Biologic Services value stream leader for the company, with responsibility for program management, quality, GMP-cell banking, clearance services, molecular biology, cell biology microbiology, virology, in vivo studies, support services and facilities. He will have direct responsibility for U.S. Biologics service delivery, quality and performance, employee development and career progression, and materials management functions.

“Jim’s accomplishments in successfully developing and implementing highly consistent, results-oriented teams, formulating business strategy, and providing collaborative leadership are substantial,” said David A. Dodd, president, chief executive officer and chairman of BioReliance. “We previously worked together very successfully at Serologicals Corp. and Jim always produced outstanding results, while developing a highly customer-oriented management team. I know we can count on him to make similarly significant contributions here at BioReliance.”

Most recently, Dr. Kramer served as senior vice president/general manager, Talecris Plasma Resources, and Talecris Biotherapeutics, a global company that provides human derived protein therapies for immunology, coagulation and alpha antitrypsin deficiency. Previously, he served at Serologicals as vice president, plasma operations and then as vice president, global manufacturing operations. Dr. Kramer also held management positions at Ortho-Clinical Diagnostics, Inc. and Pacific Hemostasis Division of Curtin Matheson Scientific.